The arachidonate 15-lipoxygenase enzyme product present in heart tissue from patients with ischaemic heart disease induces hypercoagulability

被引：0
|
作者：
Lundqvist, A. [1 ]
Hansson, G. I. [2 ]
Jeppsson, A. [3 ]
Hulten, L. Mattsson [4 ]
机构：
[1] Sahlgrens Univ Hosp, Dept Clin Chem, Gothenburg, Sweden
[2] AstraZeneca R&D, Molndal, Sweden
[3] Sahlgerenska Univ Hosp, Dept Cardiothorac Surg, Gothenburg, Sweden
[4] Sahlgrens Acad, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P4658
引用
收藏
页码：813 / 813
页数：1
相关论文
共 50 条
  • [1] The Arachidonate 15-Lipoxygenase Enzyme Product 15-HETE Is Present in Heart Tissue from Patients with Ischemic Heart Disease and Enhances Clot Formation
    Lundqvist, Annika
    Sandstedt, Mikael
    Sandstedt, Joakim
    Wickelgren, Ruth
    Hansson, Goran I.
    Jeppsson, Anders
    Hulten, Lillemor Mattsson
    PLOS ONE, 2016, 11 (08):
  • [2] High expression of arachidonate 15-lipoxygenase and proinflammatory markers in human ischemic heart tissue
    Magnusson, Lisa U.
    Lundqvist, Annika
    Asp, Julia
    Synnergren, Jane
    Johansson, Cecilia Thalen
    Palmqvist, Lars
    Jeppsson, Anders
    Hulten, Lillemor Mattsson
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 424 (02) : 327 - 330
  • [3] Systemic deficiency of mouse arachidonate 15-lipoxygenase induces defective erythropoiesis and transgenic expression of the human enzyme rescues this phenotype
    Rademacher, Marlena
    Kuhn, Hartmut
    Borchert, Astrid
    FASEB JOURNAL, 2020, 34 (11): : 14318 - 14335
  • [4] Inhibition of Arachidonate 12/15-Lipoxygenase Improves α-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients
    Chien, Yueh
    Chou, Shih-Jie
    Chang, Yuh-Lih
    Leu, Hsin-Bang
    Yang, Yi-Ping
    Tsai, Ping-Hsing
    Lai, Ying-Hsiu
    Chen, Kuan-Hsuan
    Chang, Wei-Chao
    Sung, Shih-Hsien
    Yu, Wen-Chung
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (05)
  • [5] WITHDRAWAL OF ANTICOAGULANTS FROM PATIENTS WITH ISCHAEMIC HEART DISEASE
    HEFFERNAN, A
    FARRELL, I
    IRISH JOURNAL OF MEDICAL SCIENCE, 1971, 140 (10) : 455 - +
  • [6] REHABILITATION OF PATIENTS WITH ISCHAEMIC HEART DISEASE - PRESENT STATUS OF QUESTION, AND ACTUAL PROBLEMS
    SHKHVATSABAYA, IK
    ARONOV, DM
    COR ET VASA, 1974, 16 (02) : 81 - 90
  • [7] The tissue factor tissue factor pathway inhibitor system in patients with ischaemic heart disease
    Falciani, M
    Gori, AM
    Fedi, S
    Chiarugi, L
    Simonetti, I
    Dabizzi, P
    Prisco, D
    Abbate, R
    Gensini, GF
    Serneri, GGN
    THROMBOSIS AND HAEMOSTASIS, 1997, : SC675 - SC675
  • [8] The care of patients with ischaemic heart disease from a gender perspective
    Swahn, E
    EUROPEAN HEART JOURNAL, 1998, 19 (12) : 1758 - 1765
  • [9] Cardiovascular MRI in patients with ischaemic heart disease: from science to practice?
    Hoey, Edward T. D.
    POSTGRADUATE MEDICAL JOURNAL, 2010, 86 (1019) : 513 - 514
  • [10] Elevated tissue factor and tissue factor pathway inhibitor circulating levels in Ischaemic Heart Disease patients
    Falciani, M
    Gori, AM
    Fedi, S
    Chiarugi, L
    Simonetti, I
    Dabizzi, RP
    Prisco, D
    Pepe, G
    Abbate, R
    Gensini, GF
    Serneri, GGN
    THROMBOSIS AND HAEMOSTASIS, 1998, 79 (03) : 495 - 499
12345